Abiopharma

🔍 Lewis William (Director)

Company: INSMED Inc (INSM)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 21,172 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 325,083.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: By the Katie Procter Dynasty Trust | shares_owned_after: 233,924.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: By the William Lewis Family Legacy Trust | shares_owned_after: 50,500.00
• Acquired 110,400 shares of Stock Option (right to buy) at $177.12 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 110,400.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
• F2: Each RSU was granted on January 2, 2026 for no consideration.
• F3: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.